You are not logged in.

Aptamer-targeted oligonucleotide theranostics: a smarter approach for brain delivery and the treatment of neurological diseases

Sriramoju, Bhasker, Kanwar, Rupinder, Veedu, Rakesh N. and Kanwar, Jagat R. 2015, Aptamer-targeted oligonucleotide theranostics: a smarter approach for brain delivery and the treatment of neurological diseases, Current topics in medicinal chemistry, vol. 15, no. 12, pp. 1115-1124, doi: 10.2174/1568026615666150413153928#sthash.WmB3gJkM.dpuf.

Attached Files
Name Description MIMEType Size Downloads

Title Aptamer-targeted oligonucleotide theranostics: a smarter approach for brain delivery and the treatment of neurological diseases
Author(s) Sriramoju, Bhasker
Kanwar, Rupinder
Veedu, Rakesh N.
Kanwar, Jagat R.
Journal name Current topics in medicinal chemistry
Volume number 15
Issue number 12
Start page 1115
End page 1124
Total pages 10
Publisher Bentham Science Publishers
Place of publication Bussum, The Netherlands
Publication date 2015
ISSN 1873-4294
Keyword(s) Science & Technology
Life Sciences & Biomedicine
Chemistry, Medicinal
Pharmacology & Pharmacy
Aptamers
Blood brain barrier
Nano-aptamer conjugation
Neurological diseases
Pharmacokinetics
SELEX
CENTRAL-NERVOUS-SYSTEM
RNA APTAMERS
DRUG-DELIVERY
PRION-PROTEIN
IN-VITRO
EXPONENTIAL ENRICHMENT
NOCICEPTIN/ORPHANIN FQ
AUTOMATED SELECTION
MULTIPLE-SCLEROSIS
RECEPTOR-ANTIBODY
Summary Aptamers represent the novel class of oligonucleotides holding multiple applications in the area of biomedicine. The advancements introduced with the Systematic Evolution of Ligands by EXponential enrichment (SELEX) approach further eased the scope of producing modified aptamers within a short span yet retaining the properties of stability and applicability. In the recent times, aptamers were identified to have the potential for penetrating into the deep human crevices and thus can be utilized in addressing the issues of complex neurological disorders. Considering the specificity and stability enhancement by chemical modifications, aptamer-based nanotechnologies may have great potential for future therapeutics and diagnostics (theranostics). The research community has already witnessed success with the approval of macugen (an anti-vascular endothelial growth factor aptamer) for treating degenerating eye disease, and hopefully those that are in the clinical trials will soon be translated for human application. Herein, we have summarized the aptamer chemistry, aptamer-nanoconjugates and their applications against neurological diseases.
Language eng
DOI 10.2174/1568026615666150413153928#sthash.WmB3gJkM.dpuf
Field of Research 111599 Pharmacology and Pharmaceutical Sciences not elsewhere classified
Socio Economic Objective 970111 Expanding Knowledge in the Medical and Health Sciences
HERDC Research category C1 Refereed article in a scholarly journal
ERA Research output type C Journal article
Copyright notice ©2015, Bentham Science Publishers
Persistent URL http://hdl.handle.net/10536/DRO/DU:30075684

Document type: Journal Article
Collection: Molecular and Medical Research
Connect to link resolver
 
Unless expressly stated otherwise, the copyright for items in DRO is owned by the author, with all rights reserved.

Versions
Version Filter Type
Citation counts: TR Web of Science Citation Count  Cited 1 times in TR Web of Science
Scopus Citation Count Cited 2 times in Scopus
Google Scholar Search Google Scholar
Access Statistics: 114 Abstract Views, 0 File Downloads  -  Detailed Statistics
Created: Tue, 18 Aug 2015, 15:07:08 EST

Every reasonable effort has been made to ensure that permission has been obtained for items included in DRO. If you believe that your rights have been infringed by this repository, please contact drosupport@deakin.edu.au.